Updates | Pfizer

Pfizer CEO Albert Bourla Discusses Curing the Epidemic of Exclusion at APEC CEO Summit

Read more about Pfizer CEO Albert Bourla Discusses Curing the Epidemic of Exclusion at APEC CEO Summit

This week, the annual APEC CEO Summit was held in San Francisco, California. On Thursday, Pfizer CEO Albert Bourla delivered one of the Summit CEO Spotlight speeches, with remarks focused on “Curing the Epidemic of Exclusion.”

Pfizer’s TALZENNA® in Combination with XTANDI® Receives CHMP Positive Opinion in the European Union for Adult Patients with Metastatic Castration-Resistant Prostate Cancer

Read more about Pfizer’s TALZENNA® in Combination with XTANDI® Receives CHMP Positive Opinion in the European Union for Adult Patients with Metastatic Castration-Resistant Prostate Cancer

Recommended indication is not specific to patient gene mutation status, including homologous recombination repair (HRR) gene mutations

October Social Media Round-Up—Israel-Hamas War, COVID-19 Treatment News, and Pfizer Makes Forbes List

Read more about October Social Media Round-Up—Israel-Hamas War, COVID-19 Treatment News, and Pfizer Makes Forbes List

October was an eventful month, both around the world and here at Pfizer. In this edition of the monthly social media round-up, our leadership weighs in on both.

Pfizer's COVID-19 Oral Antiviral Treatment Transitioning from Government Distribution

Read more about Pfizer's COVID-19 Oral Antiviral Treatment Transitioning from Government Distribution

As COVID-19 continues to impact our communities, and winter approaches—bringing with it increases in respiratory infections—it’s important to stay vigilant and up to date on vaccines and to understand how to access treatment when appropriate.

Pfizer’s PENBRAYA™ Receives Recommendation for Prevention of Meningococcal Disease in Adolescents and Young Adults from Advisory Committee on Immunization Practices

Read more about Pfizer’s PENBRAYA™ Receives Recommendation for Prevention of Meningococcal Disease in Adolescents and Young Adults from Advisory Committee on Immunization Practices

PENBRAYA recommended for adolescents and young adults to help protect against the five leading causes of meningococcal disease
PENBRAYA provides the broadest serogroup coverage (meningococcal group A, B, C, W, and Y) of any licensed meningococcal vaccine available in the U.S.

NEW YORK, October 25, 2023 — Pfizer Inc. (NYSE:PFE) announced today that the U.S.

Accelerating Equity Takes the Spotlight at Pfizer’s Global DEI Summit

Read more about Accelerating Equity Takes the Spotlight at Pfizer’s Global DEI Summit

On September 21, over 7,000 Pfizer colleagues and external DEI experts came together at Pfizer NYC headquarters and via webcast for the 2023 Pfizer Global DEI Summit.

Pfizer’s ELREXFIO™ Receives Positive CHMP Opinion for Relapsed and Refractory Multiple Myeloma

Read more about Pfizer’s ELREXFIO™ Receives Positive CHMP Opinion for Relapsed and Refractory Multiple Myeloma

ELREXFIO is an off-the-shelf (ready-to-use) BCMA-directed immunotherapy that induces deep and durable responses with a manageable tolerability profile, as well as convenient subcutaneous dosing

Nobel Prize Awarded to Scientists Responsible for mRNA Breakthrough

Read more about Nobel Prize Awarded to Scientists Responsible for mRNA Breakthrough

Professors at the Karolinska Institute in Stockholm awarded the 2023 Nobel Prize for Physiology or Medicine to scientists Katalin Karikó and Drew Weissman for their work in the field of modified messenger RNA (mRNA).

FDA Grants Interchangeable Designation to Pfizer’s Biosimilar ABRILADA™

Read more about FDA Grants Interchangeable Designation to Pfizer’s Biosimilar ABRILADA™

NEW YORK, October 5, 2023 – Pfizer Inc. (NYSE: PFE) today announced that the U.S. Food and Drug Administration (FDA) has designated ABRILADA™ (adalimumab-afzb) as an interchangeable biosimilar to Humira® (adalimumab). The interchangeable designation applies to all approved indications of ABRILADA, including certain patients with rheumatoid arthritis (RA), juvenile idiopathic arthritis, psoriatic arthritis, ankylosing spondylitis, Crohn's disease, ulcerative colitis, plaque psoriasis, hidradenitis suppurativa and uveitis.

September Social Media Round-Up—DEI, CMO, and Rocky Mount Resumes

Read more about September Social Media Round-Up—DEI, CMO, and Rocky Mount Resumes

Albert Bourla sitting at a roundtable discussion

This September, Albert Bourla, Pfizer’s CEO, attended Black Corporate Directors Conference to discuss minority representation across all sectors, and our social roundup starts with his thoughts on their mission. Our Chief Marketing Officer discusses his first year as Pfizer’s first CMO and where we go from here. It’s an illuminating read from an innovative thinker.

Subscribe to Updates